The inactivation of the EC system through administration of cannabinoid receptor 1 (CB1R) antagonist or CB1R knockout can ameliorate obesity-associated metabolic disorders such as insulin resistance and compensatory hyperinsulinemia and hepatic steatosis. The gene discussed is CNR1; the disease is hyperinsulinism.